BioSpace News Archive

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced that positive initial data from the first-in-human study evaluating JK08 in adults with solid tumors were presented in a poster session during the European Society of Medical Oncology Annual Congress 2023.

Geneoscopy Inc., a life sciences company focused on developing diagnostic tests for gastrointestinal health, announced a publication in The Journal of the American Medical Association (JAMA), highlighting the company’s pivotal CRC-PREVENT trial results. The novel study will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Vancouver, Canada.

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its Q3 2023 business and financial highlights before the opening of the market on October 26, 2023.

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that first Phase 1 results for BI 770371, a novel anti-SIRPα monoclonal antibody evaluated in advanced solid tumors, have been presented, at the European Society for Medical Oncology conference, held in Madrid, Spain (October 20 – 24, 2023).

35% response rate in the ADP-A2M4CD8 monotherapy cohort with ~5 months median duration of response in heavily pre-treated patients across a broad range of solid tumors

Noul Co., Ltd., an Artificial Intelligence based blood and cancer diagnostic platform company, unveiled the results of a clinical study conducted by miLab™ in two African countries.

ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has completed the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for N-803 (Anktiva®), a first-in-class IL-15 superagonist, plus Bacillus Calmette-Guérin (BCG) for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (CIS) with or without Ta or T1 disease.

Magnus Medical, Inc. announced that the American Medical Association has issued new Category III Current Procedural Terminology codes for targeted, accelerated intermittent theta burst stimulation for depression, encompassing Magnus’ SAINT™ targeted treatment.

Samsung Biologics and Kurma Partners announced a strategic partnership for the development and manufacturing of biologics for Kurma Partners’ portfolio companies.

Iterative Health, a pioneer in precision-medicine technologies for gastroenterology, announced today the results of new research unveiled at the American College of Gastroenterology (ACG) Annual Scientific Meeting.